Article info
PDFClinical and epidemiological research
Extended report
Changes in the anticitrullinated peptide antibody response in relation to therapeutic outcome in early rheumatoid arthritis: results from the SWEFOT trial
- Correspondence to Dr Alf Kastbom, Department of Rheumatology, IKE, Pathology building, floor 10, Linköping University Hospital, Linköping SE 581 85, Sweden; alf.kastbom{at}liu.se
Citation
Changes in the anticitrullinated peptide antibody response in relation to therapeutic outcome in early rheumatoid arthritis: results from the SWEFOT trial
Publication history
- Received April 8, 2014
- Revised October 31, 2014
- Accepted November 7, 2014
- First published December 30, 2014.
Online issue publication
October 25, 2017
Article Versions
- Previous version (25 October 2017).
- You are viewing the most recent version of this article.
Supplementary Data
This web only file has been produced by the BMJ Publishing Group from an electronic file supplied by the author(s) and has not been edited for content.
Files in this Data Supplement:
- Data supplement 1 - Online figure
- Data supplement 2 - Online table
Request permissions
If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.
Copyright information
Published by the BMJ Publishing Group Limited. For permission to use (where not already granted under a licence) please go to http://www.bmj.com/company/products-services/rights-and-licensing/ This is an Open Access article distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: http://creativecommons.org/licenses/by-nc/4.0/